English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Background and aims  In June 2016, the Ontario, Canada government implemented the Ontario Naloxone Program for Pharmacies (ONPP), authorizing pharmacists to provide injectable naloxone kits at no charge to all Ontario residents. In March 2018, the program was amended to include intranasal naloxone and remove the requirement to present a government health card to the dispensing pharmacist. We examined whether these changes increased naloxone dispensing through the ONPP.    Design  Population‐based time–series analysis using interventional autoregressive integrated moving average models.    Setting  Ontario, Canada.    Participants  All Ontario residents between 1 July 2016 and 31 March 2020.    Measurements  Monthly rates of pharmacy naloxone dispensing.    Findings  Overall, 199 484 individuals were dispensed a naloxone kit during the study period. In the main analysis, the rate of pharmacy naloxone dispensing increased by 65.1% following program changes (55.6–91.8 kits per 100 000 population between February 2018 and May 2018;  P  = 0.01). In subgroup analyses, naloxone dispensing increased among individuals receiving opioid agonist therapy (OAT) (3374.9–7264.2 kits per 100 000 OAT recipients;  P  = 0.04) among individuals receiving other prescription opioids (192.8–381.8 kits per 100 000 population prescribed opioids;  P  < 0.01), among individuals with past opioid exposure (134.7–205.6 kits per 100 000 population with past opioid exposure;  P  < 0.01) and in urban centers (56.2–91.4 kits per 100 000 population;  P  < 0.01). We did not observe a clear impact on pharmacy‐dispensed naloxone to individuals with no or unknown opioid exposure (34.4–39.3 kits per 100 000 population with no/unknown opioid exposure;  P  = 0.42) and in rural regions (50.4–97.2 kits per 100 000 population;  P  = 0.09).    Conclusions  Changes to the Ontario Naloxone Program for Pharmacies to add intranasal naloxone and remove the requirement to present a government health card appeared to increase pharmacy‐based naloxone dispensing uptake in Ontario, Canada, particularly among individuals at high risk of inadvertent opioid overdose.

Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population‐based time–series analysis